FRNM · Freenome

The thesis

Freenome's shares are rated more likely to lag the S&P 500 over the next three months. The 10 November 2026 third-quarter report removed the near-term funding question, but almost all of its revenue was a one-off payment tied to FDA approval. No figure yet measures colorectal test volume or royalties. The single-cancer readouts the company expects in December 2026 and the first royalty disclosure are what settle it.

The 8-K filed on 10 November 2026 shows third-quarter revenue of $183.5 million, of which $180.0 million was recognized under the Abbott collaboration and license agreement after the FDA approved SimpleScreen CRC. That amount includes the $100 million approval milestone. Service and other revenue, the line closest to Freenome's own testing, was $942 thousand. The company guided full-year 2026 revenue to $192 million to $194 million, against $183.5 million in the third quarter alone.

The balance sheet changed most. Cash, equivalents and marketable securities were $430.0 million at 30 September 2026, and operating cash flow was $38.4 million for the quarter (8-K, 10 November 2026). At 30 June 2026 the figure had been $102.0 million. The rating is Low because the remaining case depends on adoption that no reported number shows yet, while a large block of resale-registered stock still overhangs the shares.

Bullish and bearish views on Freenome, Inc.

The bull case on Freenome, Inc. (FRNM), in brief: the funding question is answered for now. The bear case: the revenue beat came from a one-time payment.

Bull case

• The funding question is answered for now. Cash and marketable securities were $430.0 million at 30 September 2026, helped by about $310 million gross raised at the 21 July 2026 listing and the approval milestone (8-K, 10 November 2026).
• The quarter beat forecasts on every headline line. Revenue of $183.5 million beat the $105.9 million estimate, and adjusted earnings per share of $1.10 beat $0.41 (earnings headlines, 10 November 2026). GAAP net income was $60.1 million, against a $64.5 million loss a year earlier.
• Debt has turned into equity. About $50.5 million of the Abbott convertible note converted into about 3.4 million shares at $15.00 per share, and the Roche note converted into about 6.4 million shares at $12.00 at the July closing (8-K, 10 November 2026).
• Two products are now on sale. Abbott launched SimpleScreen CRC in the US on 30 September 2026. Freenome launched SimpleScreen Lung as a laboratory-developed test in October 2026, with 85% sensitivity and 99.8% negative predictive value in a 172-case, 436-control cohort (Freenome release, 20 October 2026).
• Commercial payer access widens on 15 November 2026. Carelon's revised liquid-biopsy guideline takes effect that day and opens restricted coverage beyond Medicare, subject to each health plan's criteria.

Bear case

• The revenue beat came from a one-time payment. Of $183.5 million in third-quarter revenue, $182.5 million was license and collaboration revenue and $942 thousand was service revenue (8-K, 10 November 2026). The release gives no royalty line and no test volume.
• The full-year guide implies a small fourth quarter. Guidance of $192 million to $194 million for 2026 sits close to the $183.5 million booked in the third quarter, and the company says it reflects collaboration agreements, research services and "early commercial activities".
• The updated colorectal data disappointed. Updated SimpleScreen CRC detected 18.2% of advanced precancerous lesions and 80.4% of cancers at 90% specificity (Freenome release, 11 October 2026). The shares fell 11% on 13 October 2026 (TIKR).
• The lung test has weak specificity. Specificity was 50% in the launch cohort (Freenome release, 20 October 2026), so about half of people without lung cancer would test positive. The FDA Breakthrough Device Designation covers a multiomics version, and the FDA has not authorized any version for screening.
• Resale supply is large against the share count. A 18 August 2026 prospectus registered up to 75,188,742 shares for resale, against 110,870,300 shares outstanding at 30 September 2026 (8-K, 10 November 2026).
• Guidelines limit blood tests to a fallback role. The American Cancer Society's update, as Freenome summarized it on 27 May 2026, offers blood-based testing for people who decline or do not complete other recommended screening.

Price setup

The shares closed at $11.56 on 11 November 2026, up from $10.77 the session before, in the first trading day after the report. The lowest recent close was $10.18 on 6 November 2026. The 52-week closing low is $9.99 on 30 July 2026, and the 52-week intraday high is $17.50 on 21 September 2026; the last close is 33.9% below that high.

The last close sits below both the 50-day moving average of $14.2 and the 200-day moving average of $12.41, as of 11 November 2026. The shares are down 0.4% over three months, from $11.61 on 13 August 2026. The rebound after the report recovered part of the slide from October but left the price under both averages. Public trading began on 21 July 2026, so the price history covers under four months.

The only recent SEC Form 4 shows Chief Executive Officer Aaron Elliott had 71,920 shares withheld for tax at $15.25 on 2 September 2026, a routine withholding with no open-market sale.

Catalysts ahead

• 15 November 2026: Carelon revised liquid-biopsy guideline takes effect. It opens restricted commercial-payer coverage for SimpleScreen CRC beyond Medicare, subject to each health plan's criteria, and widens the pool of patients Abbott can reach.
• December 2026 (est.): Next two single-cancer readouts, which Freenome says it anticipates in December 2026. Positive data would extend the product line beyond colorectal and lung; weak data would leave the case resting on SimpleScreen CRC royalties alone.
• ~March 2027 (est.): Fourth-quarter and full-year 2026 results. It is the first quarter without the approval milestone, so it shows whether royalty and test revenue are material on their own.

What would change the view

A daily close above $14.06, the 20 October 2026 close and just under the 50-day average, which would show the shares leading the S&P 500; or a raised 2026 revenue outlook above $194 million driven by test royalties.

What it trades with

Freenome trades on its own events: FDA decisions, clinical readouts, Abbott's commercial execution and payer coverage. Abbott also sells Cologuard Plus, a stool-based colorectal test that competes with SimpleScreen CRC, so the partner's priorities shape Freenome's royalty stream. Since the 21 July 2026 listing, the price history is too short to measure a reliable relationship with the S&P 500 or a diagnostics peer group.